List view / Grid view
10 February 2016 | By Victoria White
The Breakthrough Therapy designation was based on the results of a Phase I/II trial in patients with unresectable, metastatic or recurrent synovial sarcoma...
10 February 2016 | By Victoria White
HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia...
9 February 2016 | By Victoria White
Under the extended agreement, Cytobioteck will also exclusively distribute Ruconest in Argentina, Costa Rica, the Dominican Republic and Panama...
9 February 2016 | By Victoria White
An analyst from GlobalData says promising clinical trial data for Gilotrif (afatinib) will strengthen the drug’s position in NSCLC treatment markets outside the US...
9 February 2016 | By Victoria White
The committee was unable to accept eculizumab as it was "not considered to represent an effective use of NHS Scotland’s resources"...
9 February 2016 | By Victoria White
Effective from 1st April 2016, Robinson will have responsibility for the company's operations in North and South America...
8 February 2016 | By Victoria White
The close of the transaction to combine Pfizer and Allergan is expected in the second half of 2016, and is subject to certain conditions...
8 February 2016 | By EBD Group
The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4–6, 2016...
8 February 2016 | By Victoria White
The research collaboration will test RP101 in preclinical oncology models in combination with standard-of-care chemotherapies to support existing Phase I and Phase II clinical data...
8 February 2016 | By Victoria White
Valproate is associated with a risk of birth defects and developmental disorders in children born to women who take the treatment during pregnancy...
8 February 2016 | By Victoria White
NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...
8 February 2016 | By Victoria White
The expanded label for Daklinza includes three additional patient populations: HCV patients with HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV...
5 February 2016 | By Victoria White
The companies are to are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) in FRα-positive ovarian cancer...
5 February 2016 | By Victoria White
A Public Accounts Committee has released its recommendations for the reform of the Cancer Drugs Fund...
5 February 2016 | By Honeywell
The acquisition broadens Honeywell’s research chemicals portfolio and expands the company's global reach...
